# OneTar Biomedicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/onetar-biomedicine

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.onetarjz.com/
- Latest round: Series A (Jan 21, 2026)
- Investors on record: 3

## About

Based in Shanghai, China and founded in 2020, Shanghai OneTar Biomedicine Co., Ltd., trading as OneTar Biomedicine, focuses on developing cutting-edge biopharmaceutical solutions. In January 2026, OneTar Biomedicine raised a series A funding led by new investor GSR United Capital, with participation from new investor Winreal Investment and returning investor Hefei State-Owned Assets Holding.

OneTar Biomedicine's primary offerings include a range of biopharmaceutical products designed to address various health conditions. The company develops novel therapeutics with a focus on improving treatment efficacy and patient safety. Their product pipeline aims to cater to the needs of healthcare providers and patients, facilitating better health outcomes across diverse medical fields.

The company generates revenue through various models, offering subscription-based services and commercial support for its biopharmaceutical products. Clients typically engage in contracts structured around annual agreements, ensuring access to premium features, dedicated support, and the latest therapeutic solutions tailored for their specific needs.

The company will use the latest funding to facilitate the industrialization of its organoid 'live bank' platform, providing pharmaceutical companies and research teams with a complete supply chain solution.

## Funding rounds

- Series A, Jan 21, 2026 — GSR United Capital, Winreal Investment, Hefei State-Owned Assets Holding
- Series A, Jan 9, 2026 — Hefei State-Owned Assets Holding

## Investors

- Hefei State-Owned Assets Holding (https://capitalatlas.ai/funds/hefei-state-owned-assets-holding) — Series A
- GSR United Capital (https://capitalatlas.ai/funds/gsr-united-capital) — Series A
- Winreal Investment (https://capitalatlas.ai/funds/winreal-investment) — Series A